Navigation Links
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
Date:12/5/2007

mation is intended to enhance an investor's overall understanding of the company's past financial performance and prospects for the future. For example, non-GAAP earnings per share information is an indication of the company's baseline performance before items that are considered by the company to be not reflective of the company's ongoing results. In addition, this information is among the primary indicators the company uses as a basis for evaluating company performance, allocating resources, setting incentive compensation targets, and planning and forecasting of future periods. This information is not intended to be considered in isolation or as a substitute for diluted earnings per share prepared in accordance with GAAP.

Statement on Cautionary Factors

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's financial position, results of operations, market position, product development, divestiture of the company's medical imaging business, the company's productivity transformation initiative, and business strategy. These statements may be identified by the fact that they use words such as "anticipate", "estimates", "should", "expect", "guidance", "project", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, market factors, competitive product development, pricing controls and pressures (including changes in rules and practices of managed care groups and in
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
5. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
10. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... ... next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares to ... its new report that the market drivers of this vibrant industry include increased payor ... as part of a molecular diagnostics trend. , The global market is forecast to ...
(Date:7/1/2015)... CHANDLER, Ariz. , July 1, 2015 ... announced it has earned three Gold, three Silver, and ... Business Awards gala held in Chicago ... recognized as the premier business awards program in the ... and recognizes our company,s strength in developing leaders, cultivating ...
(Date:7/1/2015)... CONNECTICUT (PRWEB) , ... July 01, 2015 , ... ... or sterilized to combat pathogen transmission. CTI’ new Medical Joysticks have an ... medical devices now have an operator control device that will increase healthcare worker ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix Corp. ... common shares of Resverlogix have approved the resolutions ... Capital Limited of 5,600,000 units at a price ... each unit being comprised of one common share ... proceeds of approximately CAD$15 million; and (ii) the ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded ... developed by the Hadassah University Hospital, Israel,s foremost medical ... (92% owned by Hadasit Bio) has completed the recruitment ... I / II clinical trial using its treatment for ...
... (NASDAQ: PRXL ), a leading global biopharmaceutical ... for the Pharmaceutical Industry in The Eighth Annual International ... honoring great performances in business.   PAREXEL was ... efficiency of clinical trials, access emerging markets, and speed ...
... have found a new way to develop straight carbon nanofibers ... for use in novel biomedical research tools, solar cells, water ... grid, and relies on ions to ensure the nanofibers are ... "This is the first time, that I know of, where ...
Cached Biology Technology:Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 2Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 3Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company 4PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 2PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 3PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 4PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 5Ions control shape of nanofibers grown on clear substrate 2Ions control shape of nanofibers grown on clear substrate 3
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... , June 24, 2015 Biometry ... with emerging biometric password solution one face in. ... one face in, entering the ... ground-breaking and affordable multifactor-authentication biometric answer to the ... technology, provided in partnership with KeyLemon, one face ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... and Gail Williams and Stockholm University's Professor Robin Room examined ... and 2002. , Their results were published in the ... Review. , The men were categorised according to ... is a marker for lower socio-economic status (SES). ...
... one-of-a-kind diamond, a unique Picasso or the switch-hitter on ... being rare has biological benefits. Professor Marla Sokolowski, a ... the 1980s discovered that a single gene affects the ... of rarity in populations of fruit flies with two ...
... Baumann, Ph.D., Assistant Investigator, and Nancy Bae, Ph.D., ... published a paper offering insight into the way ... , Published in tomorrow's issue of Molecular Cell, ... End Joining at Human Telomeric DNA Ends" employed ...
Cached Biology News:Double the death rate from cirrhosis for 'blue collar' men 2Survival of the rarest: Fruit flies shed light on the evolution of behavior 2Baumann Lab defines proteins that distinguish chromosome ends from DNA double-strand breaks 2
...
...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
MOUSE ANTI HUMAN MOC31:AZIDE FREE...
Biology Products: